5月9日，截至港股收盘，恒生指数上涨0.4%，报22867.74点。天大药业（00455.HK）收报0.162港元/ 股，上涨8.0%，成交量2000股，成交额326港元，振幅0.67%。 行业估值方面，药品及生物科技行业市盈率（TTM）平均值为5.44倍，行业中值4.53倍。天大药业市盈 率-5.26倍，行业排名第125位；其他精优药业（00858.HK）为0.72倍、金斯瑞生物科技（01548.HK）为 1.05倍、东瑞制药（02348.HK）为2.86倍、大健康国际（02211.HK）为4.14倍、帝王国际投资 （00928.HK）为4.28倍。 资料显示，天大药业有限公司(简称天大药业,香港联交所上市公司,股份代号0455)以发展中医药产业为 基础,发展创新药物和医疗科技,发展优质医疗和保健服务,致力于成为药品研制、医疗科技、中医诊疗、 健康管理领域具有市场竞争力和核心价值链的医药企业。天大药业从中医、中药、中医药智能三大方面 打造中医药全产业链,建立控制中药材品质的"天大标准",创办新型中医馆—天大馆。作为中医诊疗及健 康管理平台,天大馆秉承"上医治未病"的中医理念,恪守"中病即止,以人为本"的治疗 ...

Regulatory Approvals - Tianda Pharmaceuticals received drug registration approval for "Nicorandil for Injection" from the National Medical Products Administration of China[15]. - Tianda Pharmaceutical Technology (Zhuhai) Co., Ltd. obtained drug registration approval for "Ibuprofen suspension" from the National Medical Products Administration of China[16]. - In 2024, the Group has received drug registration approvals for 4 new varieties, including pediatric drugs and a cardiocerebrovascular drug, which are expected to drive new growth momentum[75]. Corporate Social Responsibility - Tianda Pharmaceuticals was awarded the "Caring Company" logo for the fourth consecutive year by the Hong Kong Council of Social Service[13]. - Tianda Pharmaceuticals was recognized as a "Happy Company" under the "Happiness-at-Work Promotional Scheme" by the Promoting Happiness Index Foundation[12]. - The Group has conducted over 40 charity clinic sessions and organized numerous TCM-themed activities to promote TCM knowledge in the community[68]. Business Operations and Strategy - The company operates multiple TDMall locations, including in Jordan and Causeway Bay, enhancing its market presence[20][21]. - The Group's strategy includes the "Three Developments" focusing on Chinese medicine, innovative drugs, and quality healthcare services, aiming to consolidate core products and expand sales channels[39][42]. - The Group plans to launch three new products in 2025, enhancing its product pipeline and focusing on R&D for innovative drugs and consumer healthcare products[40][43]. - The Group opened its sixth TDMall globally and fifth in the Greater Bay Area in October 2024, aiming to establish it as an oncology treatment center[45]. - The Group aims to promote a collaborative development model of "drugs + medical services" to enhance the quality of the Chinese medicine business[46]. Financial Performance - The Group's total revenue for the Year was HK$329.9 million, a significant decline from HK$532.1 million in the Previous Financial Year, resulting in increased losses attributable to shareholders from HK$24.2 million to HK$61.4 million[52]. - Revenue from the Pharmaceuticals and medical technologies business was HK$283.9 million, down 39.7% from HK$470.7 million in the Previous Financial Year, primarily due to decreased demand for Tuoen® Ibuprofen and competitive pricing strategies affecting Tuoping® Valsartan capsules[82]. - The loss attributable to shareholders increased from HK$24.2 million to HK$61.4 million, reflecting the overall decline in business performance[89]. Governance and Management - The Company emphasizes corporate governance with various committees including Audit, Remuneration, and Risk Management[5]. - The Company has complied with the Corporate Governance Code during the year, except for the separation of the roles of Chairman and CEO[104]. - The Board consists of 6 male Directors and 1 female Director, including 2 Executive Directors and 3 Independent Non-executive Directors[110]. - The Company has established various committees, including the audit, nomination, remuneration, and risk management committees, primarily composed of INEDs[133]. - The Board has developed and reviewed policies related to Board diversity and shareholder communication[126]. Research and Development - The Group's R&D projects include one Class 1 TCM innovative drug, three Class 3 TCM new drugs, and twelve chemical generic drugs, indicating a rich R&D pipeline[74]. - The Group is focusing on the R&D of traditional Chinese medicine, aiming for stronger R&D, larger markets, and enhanced efficacy through technological advancements and resource growth[64]. - The Group is advancing the Phase II clinical trials of a Class 1 TCM innovative drug for chronic heart failure, highlighting its commitment to innovative medicine[76]. Market Challenges and Outlook - In 2024, the pharmaceutical market faced challenges due to economic uncertainty, with a focus on respiratory infection and antihypertensive drugs struggling to grow as inventory clearance continued post-pandemic[39][42]. - The Chinese medicine segment faced a decline in end-user demand due to the economic environment, impacting trading and production of Chinese medicinal materials[41][43]. - Future market demand is expected to improve as the economy recovers and national policies supporting the pharmaceutical industry are enhanced[46]. Human Resources - As of December 31, 2024, the Group employed approximately 701 employees across Hong Kong, the PRC, and Australia[99]. - The board currently consists of 6 male and 1 female directors, with female representation at approximately 48% at the workforce level[155].

（以上内容为金融界基于公开消息，由程序或算法智能生成，不作为投资建议或交易依据。） 来源：金融界 截至4月10日收盘，天大药业（00455.HK）报0.136港元，较上个交易日下跌12.26%，当日盘中最低价 触及0.135港元，创近一年新低。 资金流向方面，当日主力流入0.000万港元，流出0.297万港元，净流出0.30万港元。 天大药业有限公司(简称天大药业,香港联交所上市公司,股份代号0455)以发展中医药产业为基础,发展创 新药物和医疗科技,发展优质医疗和保健服务,致力于成为药品研制、医疗科技、中医诊疗、健康管理领 域具有市场竞争力和核心价值链的医药企业。天大药业从中医、中药、中医药智能三大方面打造中医药 全产业链,建立控制中药材品质的"天大标准",创办新型中医馆—天大馆。作为中医诊疗及健康管理平台, 天大馆秉承"上医治未病"的中医理念,恪守"中病即止,以人为本"的治疗准则,立足粤港澳大湾区,布局全国 全球,努力发展成为中医馆第一品牌;并充分利用互联网资讯技术、大数据、人工智能及其它创新科技,搭 建"云上天大馆",实现中医药服务线上线下相互融合、远端诊疗及专家会诊,为民众提供优质、便捷、全 面的中医 ...

年報 2023 19 MANAGEMENT DISCUSSION AND ANALYSIS 管理層討論與分析 TDMall growing with innovative business model to promote TCM culture The Group created the new type Chinese medicine clinic brand "TDMall", with the core positioning of "specialist treatments and specialized services, effectiveness and efficacy, combination of recovery and health-preservation, and harmony between nature and mankind". Since the opening of its first flagship in 2019, TDMall continuously improved its medical system, operation system, marke ...

Annual Report 2022 (For The Nine Months Ended 31 December 2022) CONTENTS 目錄 2 Corporate Information 公司資料 5 Corporate Structure 企業架構 8 Biographical Details of Directors 董事簡歷 11 Report of the Chairman 董事長報告 13 Management Discussion and Analysis 管理層討論與分析 21 Corporate Governance Report 企業管治報告 44 Report of the Directors 董事會報告 58 Independent Auditor’s Report 獨立核數師報告 65 Consolidated Statement of Profit or Loss and 綜合損益及其它全面收益表 Other Comprehensive Income 67 Consolidated Statement of Financial Position 綜合財務狀況表 69 Co ...

天大藥業有限公司 TIANDA PHARMACEUTICALS LIMITED 股份代號 Stock Code: 00455 ( 於開曼群島註冊成立之公司 ) ( Incorporated in the Cayman Islands with limited Tability ) Interim Report 2022 01 CONTENTS 目錄 2 Corporate Information 3 Management Discussion and Analysis 9 Disclosure of Interests and Other Information 12 公司資料 13 管理層討論與分析 19 權益披露及其它資料 22 Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income 簡明綜合損益及其它全面收益表 24 Condensed Consolidated Statement of Financial Position 簡明綜合財務狀況表 26 Condensed Consolidated ...

Rep 天大藥業有限公司 TIANDA PHARMACEUTICALS LIMITED 股份代號 Stock Code: 00455（於開曼群島註冊成立之公司） (Incorporated in the Cayman Islands with limited liability) Annual Report 2022 CONTENTS 目錄 | --- | --- | --- | |-------|-------|--------------------------| | | | | | | 2 Corporate Information | 公司資料 | | | 5 Corporate Structure | 企業架構 | | | 8 Biographical Details of Directors | 董事簡歷 | | | 12 Report of the Chairman | 董事長報告 | | | 14 Management Discussion and Analysis | 管理層討論與分析 | | | 19 Corporate Governance Report | 企業管治報告 | | | 3 ...

天大藥業有限公司 TIANDA PHARMACEUTICALS LIMITED 股份代號 Stock Code: 00455 ( 於開曼群島註冊成立之公司 ) ( Incorporated in the Cayman Islands with limited Tability ) Interim Report 2021 01 CONTENTS 目錄 2 Corporate Information 3 Management Discussion and Analysis 8 Disclosure of Interests and Other Information 11 公司資料 12 管理層討論與分析 17 權益披露及其它資料 20 Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income 簡明綜合損益及其它全面收益表 22 Condensed Consolidated Statement of Financial Position 簡明綜合財務狀況表 24 Condensed Consolidated ...

Rep 天大藥業有限公司 TIANDA PHARMACEUTICALS LIMITED 股份代號 Stock Code: 00455（於開曼群島註冊成立之公司） (Incorporated in the Cayman Islands with limited liability) Annual Report 2021 CONTENTS 目錄 | --- | --- | --- | |-------|-------|--------------------------| | | | | | | 2 Corporate Information | 公司資料 | | | 5 Corporate Structure | 企業架構 | | | 8 Biographical Details of Directors | 董事簡歷 | | | 13 Report of the Chairman | 董事長報告 | | | 16 Management Discussion and Analysis | 管理層討論與分析 | | | 24 Corporate Governance Report | 企業管治報告 | | | 4 ...

Re 天 大 藥 業 有 限 公 司 TIANDA PHARMACEUTICALS LIMITED 股份代號 Stock Code: 00455 ( 於開曼群島註冊成立之公司 ) ( Incorporated in the Cayman Islands with limited Kability } Interim Report 2020 01 CONTENTS 目錄 | --- | --- | |-------|-----------------------------------------------------------------------------------------------------------------| | | | | | | | 2 | Corporate Information | | 3 | Highlights | | 4 | Management Discussion and Analysis | | 9 | Disclosure of Interests and Other Information | | 12 | 公司資料 | | 13 | 摘要 | | 14 ...